In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Daiichi buys Plexxikon for $805mm up front, plus earn-outs

Executive Summary

Daiichi Sankyo Co. Ltd. will pay $805mm in cash to acquire privately held drug discovery company Plexxikon Inc., a move that will greatly expand the Japanese pharmaco's oncology business. The deal has also been sweetened with up to $130mm in launch-related earn-outs based on PLX4032, Plexxikon's lead candidate for malignant melanoma.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash

Related Companies